Latest Hotspot

Edgewise Therapeutics Starts Phase 2 Trial of EDG-7500 for Obstructive HCM

7 May 2024
3 min read

Edgewise Therapeutics, Inc., a prominent biopharmaceutical enterprise specializing in muscle disorders, revealed the initiation of the first patient dosing in the Phase 2 CIRRUS-HCM trial for their drug EDG-7500. EDG-7500, an innovative oral compound, acts as a selective modulator of the cardiac sarcomere. It is tailored to decrease the early velocity of contraction and alleviate the issues related to cardiac relaxation seen in HCM and additional diastolic dysfunction conditions.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The Phase 2 study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of EDG-7500 in individuals diagnosed with obstructive HCM. The study will be conducted in two parts; Part A will focus on the effects of single dose administrations, whereas Part B will explore the consequences of multiple oral doses administered over a span of 28 days.

Marc Semigran, M.D., Chief Development Officer at Edgewise Therapeutics, expressed optimism regarding preliminary findings, stating, "In a relevant animal model of obstructive HCM, EDG-7500 effectively reduced the gradient at the left ventricular outflow tract and maintained normal LV contractility levels. Notably, EDG-7500 administration, in both short-term and long-term durations, in models representing non-obstructive HCM, displayed substantial enhancements in both ventricular filling and diastolic function."

Further, Kevin Koch, Ph.D., President and CEO of Edgewise Therapeutics, emphasized the significance of progressing EDG-7500 studies in patients with obstructive HCM: "This step is a critical achievement for Edgewise and reflects our solid expertise in discovery and development, underscoring our dedication to addressing severe muscular disorders."

Edgewise Therapeutics anticipates releasing findings from the single dose segment of this trial alongside data from a Phase 1 study involving healthy volunteers during the third quarter of 2024. Additionally, there are plans to commence a 28-day study including patients with both obstructive and non-obstructive HCM in the latter half of 2024. An open-label extension study for EDG-7500 is also projected to begin in the last quarter of 2024.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of May 6, 2024, there are 19 investigational drugs for the cardiac myosin targets, including 21 indications, 15 R&D institutions involved, with related clinical trials reaching 86, and as many as 1577 patents.

EDG-7500 is a drug developed by Edgewise Therapeutics, Inc. that targets cardiac myosin and aims to address hypertrophic obstructive cardiomyopathy. With its current status in Phase 2 of development, EDG-7500 shows promise as a potential treatment option for patients suffering from this cardiovascular disease. Further research and clinical trials will be necessary to determine the drug's safety and efficacy before it can be made available to patients.

图形用户界面, 文本, 应用程序

描述已自动生成

What are immune checkpoints?
"What" Series
2 min read
What are immune checkpoints?
7 May 2024
Immune checkpoints are a class of regulatory molecules in the immune system that are expressed on immune cells such as T cells and can modulate the intensity and duration of immune responses.
Read →
Fate Therapeutics Presents Preliminary FT522 Data for Autoimmune Diseases at ASGCT
Latest Hotspot
3 min read
Fate Therapeutics Presents Preliminary FT522 Data for Autoimmune Diseases at ASGCT
7 May 2024
Fate Therapeutics Reveals FT522 Early-Stage Data on Autoimmune Disorders in a New Abstract at the ASGCT Annual Conference.
Read →
What ADC-related progress will Innovent Biologics reveal at the ASCO conference?
Hot Spotlight
3 min read
What ADC-related progress will Innovent Biologics reveal at the ASCO conference?
7 May 2024
Innovent Biologics will present a poster demonstrating the safety and efficacy of IBI343 in patients with advanced pancreatic ductal adenocarcinoma or cholangiocarcinoma.
Read →
HanAll Biopharma Initiates Phase III VELOS-4 Trial of Tanfanercept for Dry Eye Syndrome
Latest Hotspot
3 min read
HanAll Biopharma Initiates Phase III VELOS-4 Trial of Tanfanercept for Dry Eye Syndrome
7 May 2024
HanAll Biopharma Launches Phase III Double-Blind, Placebo-Controlled VELOS-4 Study to Assess Tanfanercept in Treating Dry Eye Syndrome.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.